Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’s

New data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and secondary care

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 (AAIC®) in London on July 12-15. These data demonstrate how Genentech and Roche are advancing the development of next-generation medicines and diagnostic tests, driven by a mission to slow, stop or even prevent the progression of Alzheimer’s disease. In total, there are 18 oral and poster presentations. Highlights include five oral presentations as part of a trontinemab Featured Research Session, an oral Perspectives Session on neuroimmune targets such as NLRP3 for neurodegenerative diseases, and presentations on the use of Roche's Elecsys® pTau217 and pTau181 blood tests to support Alzheimer’s disease diagnosis.